Aethlon Medical Inc. Files 10-Q for Period Ending December 31, 2023

TL;DR

<b>Aethlon Medical Inc. filed its quarterly report (10-Q) for the period ending December 31, 2023, detailing its financial performance and operational status.</b>

AI Summary

AETHLON MEDICAL INC (AEMD) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Aethlon Medical Inc. filed a 10-Q report for the period ending December 31, 2023. The filing covers the third quarter of fiscal year 2024. The company's fiscal year ends on March 31st. Aethlon Medical Inc. is incorporated in Nevada. The company's business address is in San Diego, CA.

Why It Matters

For investors and stakeholders tracking AETHLON MEDICAL INC, this filing contains several important signals. This filing provides investors with an update on Aethlon Medical's financial health and strategic direction for the third quarter of fiscal year 2024. Understanding the details within this 10-Q is crucial for assessing the company's progress in its market and its ability to meet future financial obligations.

Risk Assessment

Risk Level: low — AETHLON MEDICAL INC shows low risk based on this filing. The filing is a standard 10-Q report, providing routine financial disclosures without immediate indicators of significant financial distress or major positive developments.

Analyst Insight

Review the detailed financial statements and management discussion within the 10-Q to understand Aethlon Medical's current operational performance and future outlook.

Key Numbers

• 20231231 — Period End Date (10-Q filing)
• 20240214 — Filing Date (10-Q filing)
• 0331 — Fiscal Year End (Company fiscal year)
• Q3 — Fiscal Quarter (Reported period)

Key Players & Entities

• AETHLON MEDICAL INC (company) — Filer name
• 0001683168-24-000993 (filing_id) — Accession number
• 20240214 (date) — Filing date
• 20231231 (date) — Period of report
• 0000882291 (company_id) — Central Index Key
• 3841 (industry_code) — Standard Industrial Classification
• NV (state) — State of incorporation
• 11555 SORRENTO VALLEY ROAD, SUITE 203 (address) — Business address

FAQ

Industry Context

Aethlon Medical Inc. operates in the surgical and medical instruments & apparatus industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and net income.
2. Review management's discussion and analysis for insights into business operations and strategy.
3. Check for any updates on product development, clinical trials, or regulatory approvals.

Year-Over-Year Comparison

This is the initial 10-Q filing for the period ending December 31, 2023, and no prior period comparison data is available within this specific document extract.

Key Financial Figures

• $0.001 — t: TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAM

Filing Documents

• aethlon_i10q-123123.htm (10-Q) — 588KB
• aethlon_ex3101.htm (EX-31.1) — 9KB
• aethlon_ex3201.htm (EX-32.1) — 5KB
• 0001683168-24-000993.txt (&nbsp;) — 3152KB
• aemd-20231231.xsd (EX-101.SCH) — 31KB
• aemd-20231231_cal.xml (EX-101.CAL) — 37KB
• aemd-20231231_def.xml (EX-101.DEF) — 107KB
• aemd-20231231_lab.xml (EX-101.LAB) — 219KB
• aemd-20231231_pre.xml (EX-101.PRE) — 182KB
• aethlon_i10q-123123_htm.xml (XML) — 368KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 4 CONDENSED CONSOLIDATED BALANCE SHEETS AT DECEMBER 31, 2023 (UNAUDITED) AND MARCH 31, 2023 4 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED) 5 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED) 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED) 7 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 8 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 17 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 24 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 24 PART II. OTHER INFORMATION 25 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 25 ITEM 1A.

RISK FACTORS

RISK FACTORS 25 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 26 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 26 ITEM 4. MINE SAFETY DISCLOSURES 26 ITEM 5. OTHER INFORMATION 26 ITEM 6. EXHIBITS 27

SIGNATURES

SIGNATURES 28 2 CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections. We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Quarterly Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of future clinical trials, and capital outlook, successful completion of our clinical trials, our ability to raise additional capital, our ability to maintain our Nasdaq listing, U.S. Food and Drug Administration, or FDA, approval of our products candidates, our ability to comply with changing government regulations, patent protection of our proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with the Securities and Exchange Commission, or the SEC. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2023 March 31, 2023 (Unaudited) ASSETS Current assets Cash $ 7,972,012 $ 14,532,943 Prepaid expenses and other current assets 277,321 557,623 Total current assets 8,249,333 15,090,566 Property and equipment, net 1,113,880 1,144,004 Right-of-use lease asset, net 951,466 1,151,909 Patents, net 1,238 1,650 Restricted cash 87,506 87,506 Deposits 33,305 33,305 Total assets $ 10,436,728 $ 17,508,940 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 693,154 $ 432,890 Due to related parties 656,045 214,221 Lease liability, current portion 285,095 269,386 Other current liabilities 466,329 588,592 Total current liabilities 2,100,623 1,505,089 Lease liability, less current portion 724,848 939,642 Total liabilities 2,825,471 2,444,731 Stockholders' Equity Common stock, par value $ 0.001 per share; 60,000,000 shares authorized as of December 31, 2023 and March 31, 2023; 2,596,538 and 2,299,259 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively 2,596 2,299 Additional paid-in capital 159,751,591 157,426,606 Accumulated other comprehensive loss ( 1,619 ) ( 6,141 ) Accumulated deficit ( 152,141,311 ) ( 142,358,555 ) Total stockholders' equity 7,611,257 15,064,209 Total liabilities and stockholders' equity $ 10,436,728 $ 17,508,940 The accompanying notes are an integral part of these condensed consolidated financial statements . 4 AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three and Nine Month Periods Ended December 31, 2023 and 2022 (Unaudited) Three Months Ended December 31, 2023 Three Months Ended December 31, 2022 Nine Months Ended December 31, 2023 Nine Months Ended December 31, 2022 OPERATING EXPENSES

View Full Filing

View this 10-Q filing on SEC EDGAR